$400.6 M

CASI Mkt cap, 04-Dec-2018
CASI Pharmaceuticals Net income (Q3, 2018)-8.8 M
CASI Pharmaceuticals Cash, 30-Sep-201898.9 M
CASI Pharmaceuticals EV303.2 M

CASI Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

23.7k47.7k

Revenue growth, %

(100%)101%

Cost of goods sold

7.5k6.3k

Gross profit

16.3k41.4k

Gross profit Margin, %

69%87%

R&D expense

2.7m2.8m4.1m4.6m7.6m

General and administrative expense

3.0m3.8m3.1m4.8m3.2m

Operating expense total

5.7m26.2m7.2m9.4m10.8m

EBIT

(5.7m)

Interest expense

26.6k81.5k26.1k

Net Income

(5.7m)(5.7m)(26.2m)(7.2m)(9.5m)(10.8m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cost of goods sold

6.3k2.7kwdxefcqufszuzezftuxetqsqxt

R&D expense

793.8k560.0k724.5k697.0k865.0k1.2m942.3k1.0m1.4m1.0m1.0m1.7m971.0k1.7m1.7m1.8m

General and administrative expense

648.7k891.4k891.9k1.2m924.8k857.6k673.9k765.1k1.9m676.9k644.2k691.4k625.9k1.3m4.0m6.9m

Operating expense total

1.4m1.5m1.6m1.8m1.8m2.1m1.6m1.8m3.3m1.7m1.7m2.4m1.6m3.0m8.8m8.7m

Depreciation and amortization

69.4k

Interest expense

24.2k24.3k24.3k8.8k8.8k5.6k546.0

Interest income

384.0129.06.7k

Net Income

(1.4m)(1.5m)(1.6m)(21.5m)(1.8m)(2.1m)(1.6m)(1.8m)(3.3m)(1.7m)(1.7m)(2.4m)(1.6m)(3.6m)(5.9m)(8.8m)

CASI Pharmaceuticals Balance Sheet

Annual

USDY, 2009Y, 2010Y, 2011Y, 2012FY, 2013Y, 2013Y, 2014Y, 2015FY, 2015FY, 2016FY, 2017

Cash

6.3m4.9m1.1m8.0m15.1m15.1m10.7m5.1m5.1m27.1m43.5m

Accounts Receivable

Inventories

Current Assets

15.4m15.4m11.0m5.6m5.6m27.4m43.8m

PP&E

78.1k78.1k261.8k218.8k218.8k229.6k1.0m

Total Assets

15.5m15.5m11.3m5.8m5.8m27.7m45.1m

Accounts Payable

402.5k402.5k754.6k884.1k884.1k1.1m2.1m

Short-term debt

1.5m1.5m

Current Liabilities

565.2k565.2k919.0k1.1m1.1m1.3m5.1m

Long-term debt

Total Debt

1.5m1.5m

Total Liabilities

11.9m6.9m6.6m

Additional Paid-in Capital

421.8m421.8m432.6m434.1m434.1m470.1m498.6m

Retained Earnings

(399.1m)(399.1m)(425.3m)(432.5m)(432.5m)(441.9m)(452.7m)

Total Equity

14.9m14.9m(422.2k)(6.1m)20.8m38.5m

Shares Outstanding

28.6m32.4m

Financial Leverage

1 x1 x-26.8 x-1 x1.3 x1.2 x

CASI Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(5.7m)(26.2m)(7.2m)(9.5m)(10.8m)

Depreciation and Amortization

17.4k48.2k68.4k66.5k117.8k

Accounts Receivable

669.3k(23.7k)23.7k

Inventories

Accounts Payable

(102.4k)352.2k129.5k180.5k849.4k

Cash From Operating Activities

(3.3m)(4.0m)(5.5m)(6.0m)(6.4m)

Purchases of PP&E

(934.7k)

Cash From Investing Activities

(43.0k)(466.3k)(25.4k)(64.8k)(934.7k)

Cash From Financing Activities

10.4m28.0m23.7m

Interest Paid

7.5k

CASI Pharmaceuticals Ratios

USDY, 2018

EV/CFO

-23.5 x

Financial Leverage

1.1 x
Report incorrect company information